Administering chemotherapy before radiotherapy is linked with increased overall survival for patients with NSCLC with disease metastasis after undergoing resection.

News

A recent phase III trial showed a combination regimen with immunotherapy agents plus chemotherapy significantly reduced the risk of disease progression or death in patients with advanced non-squamous non-small cell lung cancer.

A recent study compared the effectiveness of stereotactic ablative body radiotherapy (SABR) with conventional full fractionated radiotherapy (CRT) in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer (NSCLC), presented at the International Association for the Study of Lung Cancer 18th Annual World Conference (October 15-

Read More

Despite the majority of radiation oncologists administering the National Comprehensive Cancer Network (NCCN) guideline-recommended thoracic radiotherapy schedule to patients with small-cell lung cancer, great variability still exists in dosing and fractionation, according to a recent survey.

Read More

A liquid biopsy that measures circulating lung tumor DNA at the end of treatment identifies patients with early non-small cell lung cancer (NSCLC) with a poor prognosis, according to research presented at the American Society for Radiation Oncology (ASTRO) annual meeting (September 24-27, 2017; San Diego, CA).

Read More

Research in Review

Aggressive care within the last month of life for patients with non-small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care, according to new research.

-----

Related Content

Read More

Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according to a presentation at the European Lung Cancer Conference (Geneva, Switzerland; abstract 91PD).

-----

Related Content

Read More

Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the European Lung Cancer Conference (April 25, 2017; abstract 112P_PR).

-----

Related Content

Read More

None of the patients in a study with lung cancer and hepatic metastases experienced an objective response in their liver tumors after anti-PD1 therapy, according to research presented at ASCO’s Society for Immunotherapy of Cancer’s 2017 Clinical Immuno-Oncology Symposium (February 23-25, 2017; abstract 38).

-----

Related Content

Read More

Subscribe to Lung Cancer

Ad-Lung Cancer MRC-Desktop Crawler